How can generic enterprises survive in the era of centralized purchase

[pharmaceutical network market analysis] what words are very popular in the pharmaceutical industry in 2019? It should not be "centralized procurement"! The chain effect of centralized mining not only has a profound impact on China's pharmaceutical industry, but also closely related to every consumer However, with the national promotion of centralized procurement spreading gradually, the shortage of generic pharmaceutical enterprises is becoming increasingly difficult, especially a large number of small and medium-sized pharmaceutical factories, as if they would be abandoned by the market accidentally Photo source: in response to this situation, some insiders said, "now, people talk about the color change of generic drugs, many enterprises do not do generic drugs; a large number of enterprises give up the consistency evaluation of generic drugs; the capital market is no longer optimistic about generic drugs." Therefore, a large number of pharmaceutical enterprises have begun to take the road of transformation and innovation, and the typical representative of such enterprises is Hengrui pharmaceutical, which has said to the outside that it will stop a batch of general generic drug research and development, including some of which have been carried out to the later stage, and only do innovative drugs and valuable high-end generic drugs in the future It is reported that at present, there are 4441 pharmaceutical enterprises and 3262 pharmaceutical enterprises in China, 99% of which are generic and do not have great innovation ability How can these enterprises survive in the face of complex and changeable market environment? To be difficult to imitate and new dosage form enterprises, although they are all talking about making innovative drugs, in fact, there are less than 300 pharmaceutical enterprises with the ability of R & D resource team platform Now it is too early to say that the generic pharmaceutical industry will be eliminated At present, the volume of purchased products still accounts for a small number in the whole pharmaceutical market, and a large number of chemical generic drugs still have market demand At present, pharmaceutical companies should first clarify the product strategy and what can be caught from the existing policies and opportunities, such as children's medicine or cancer medicine Enterprises without R & D capabilities simply purchase projects and participate in the new generic pharmaceutical market through acquisition and cooperation Focus on the main business and highlight the competitive advantage Some insiders said that in the next five years, the preparation process will be improved rapidly, so there will be more opportunities for generic drugs and preparations After all, many improved new drugs are the improvement of preparations Therefore, in the past 40 years, although local enterprises do not pay much attention to preparation technology, a number of enterprises have begun to catch up in recent years At present, there are 400 andas in the United States, compared with 4000-5000 in India, which has great potential for development It is also unknown that generic pharmaceutical companies will seize the pharmaceutical market from the side in the future With the continuous deepening of volume purchasing, generic pharmaceutical products are facing the test of "price" and "volume" For the bid winning enterprises, due to the high demand for production capacity, the industrial pressure is allocated to every stage from API procurement to pharmaceutical production and distribution In this context, the advantages of enterprises with the integrated development mode of APIs will be gradually highlighted Taking Beijing new pharmaceutical industry as an example, it started with quinolones such as levofloxacin, ciprofloxacin and enrofloxacin With the continuous layout of the company in the field of cardiovascular and neurology, together with the advent of finished drugs such as rosuvastatin and levetiracetam, the varieties of characteristic APIs are gradually enriched, which have included preparation products in multiple treatment fields, and formed an integrated advantage of "API + Preparation" Some experts believe that there are more than 1000 kinds of clinical diseases, involving more than 12000 kinds of drugs, some of which will still be made by enterprises even if the price is reduced to one or two yuan and the profit is very thin, because it can control raw materials and intermediates With the advantages of integration of raw materials and preparations, it can reduce costs, save circulation costs and gold costs, and still make money In the future, enterprises that can survive well will be very strong in the industrial chain Therefore, enterprises should not only pursue hot categories, but also study many varieties in the market in depth, pay attention to quantitative analysis, and see which varieties have less application consistency evaluation, how big the market will be, whether they can master the raw materials, whether they can match their own enterprises, etc after they have determined, they can carry out research and development, and then make this category specialized.